CA2247848C - Nitric oxide donors capable of reducing toxicity from drugs - Google Patents

Nitric oxide donors capable of reducing toxicity from drugs Download PDF

Info

Publication number
CA2247848C
CA2247848C CA002247848A CA2247848A CA2247848C CA 2247848 C CA2247848 C CA 2247848C CA 002247848 A CA002247848 A CA 002247848A CA 2247848 A CA2247848 A CA 2247848A CA 2247848 C CA2247848 C CA 2247848C
Authority
CA
Canada
Prior art keywords
drug
use according
formula
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002247848A
Other languages
English (en)
French (fr)
Other versions
CA2247848A1 (en
Inventor
Piero Del Soldato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11373387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2247848(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicox SA filed Critical Nicox SA
Publication of CA2247848A1 publication Critical patent/CA2247848A1/en
Application granted granted Critical
Publication of CA2247848C publication Critical patent/CA2247848C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Underground Structures, Protecting, Testing And Restoring Foundations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CA002247848A 1996-02-26 1997-02-24 Nitric oxide donors capable of reducing toxicity from drugs Expired - Fee Related CA2247848C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI96A000352 1996-02-26
IT96MI000352A IT1282686B1 (it) 1996-02-26 1996-02-26 Composti in grado di ridurre la tossicita' da farmaci
PCT/EP1997/000873 WO1997031654A1 (en) 1996-02-26 1997-02-24 Nitric oxide donors capable of reducing toxicity from drugs

Publications (2)

Publication Number Publication Date
CA2247848A1 CA2247848A1 (en) 1997-09-04
CA2247848C true CA2247848C (en) 2008-07-15

Family

ID=11373387

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247848A Expired - Fee Related CA2247848C (en) 1996-02-26 1997-02-24 Nitric oxide donors capable of reducing toxicity from drugs

Country Status (16)

Country Link
US (1) US7087588B2 (h)
EP (2) EP0904110B1 (h)
JP (1) JP2000506133A (h)
KR (1) KR19990087113A (h)
AT (1) ATE220920T1 (h)
AU (1) AU706591B2 (h)
BR (1) BR9707739A (h)
CA (1) CA2247848C (h)
DE (1) DE69714253T2 (h)
DK (1) DK0904110T3 (h)
ES (1) ES2180938T3 (h)
HU (1) HUP9900993A3 (h)
IT (1) IT1282686B1 (h)
PT (1) PT904110E (h)
RU (1) RU2192247C2 (h)
WO (1) WO1997031654A1 (h)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
IT1298338B1 (it) * 1998-03-05 1999-12-20 Nicox Sa Composizioni farmaceutiche per l'ulcera
US6297260B1 (en) 1998-10-30 2001-10-02 Nitromed, Inc. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
EP1251840A2 (en) * 2000-01-26 2002-10-30 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
EP1406609B1 (en) 2000-12-21 2006-09-06 Nitromed, Inc. Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
US7211561B2 (en) 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
ATE310514T1 (de) 2002-04-19 2005-12-15 Yissum Res Dev Co Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1539679A4 (en) 2002-06-28 2007-07-04 Nitromed Inc OXIM- AND / OR HYDRAZO-CONTAINING, NITROSED AND / OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND USE METHODS
WO2004004648A2 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
EP1542972A4 (en) 2002-07-29 2008-01-23 Nitromed Inc CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITION AND METHOD OF USE
SE0300971D0 (sv) * 2003-04-03 2003-04-03 Aga Ab Nitric oxide in treatment of inflammation
WO2005070868A1 (en) * 2004-01-27 2005-08-04 Merck Frosst Company Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
KR20070045187A (ko) * 2004-06-10 2007-05-02 고쿠리츠다이가쿠호진 도호쿠다이가쿠 항암제의 효과 증강제
JP2007325501A (ja) * 2004-08-25 2007-12-20 Tottori Univ 非ステロイド性抗炎症薬による動物の消化管副作用の予防・治療方法
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
US20100240745A1 (en) * 2009-03-20 2010-09-23 Nicox S.A. Method of treatment of inflammation in hypertensive patients
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
EP4249001A3 (en) 2009-08-21 2023-11-29 Novan, Inc. Topical gels
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
RU2539630C1 (ru) * 2013-07-09 2015-01-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии сетчатки в эксперименте

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
EP0722434B1 (en) 1993-10-06 1998-07-29 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US5861426A (en) 1994-05-10 1999-01-19 Nicox S.A. Nitro compounds of the formula A-Xi -NO2 and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5620416A (en) 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents

Also Published As

Publication number Publication date
CA2247848A1 (en) 1997-09-04
HUP9900993A2 (hu) 1999-09-28
US7087588B2 (en) 2006-08-08
ES2180938T3 (es) 2003-02-16
EP0904110B1 (en) 2002-07-24
BR9707739A (pt) 1999-07-27
RU2192247C2 (ru) 2002-11-10
HUP9900993A3 (en) 2000-10-30
AU706591B2 (en) 1999-06-17
ATE220920T1 (de) 2002-08-15
EP1221326A2 (en) 2002-07-10
WO1997031654A1 (en) 1997-09-04
PT904110E (pt) 2002-12-31
IT1282686B1 (it) 1998-03-31
DK0904110T3 (da) 2002-11-11
DE69714253D1 (de) 2002-08-29
AU2092497A (en) 1997-09-16
EP0904110A1 (en) 1999-03-31
JP2000506133A (ja) 2000-05-23
KR19990087113A (ko) 1999-12-15
DE69714253T2 (de) 2003-03-06
US20040242651A1 (en) 2004-12-02
EP1221326A3 (en) 2004-01-14
ITMI960352A1 (it) 1997-08-26
ITMI960352A0 (h) 1996-02-26

Similar Documents

Publication Publication Date Title
CA2247848C (en) Nitric oxide donors capable of reducing toxicity from drugs
Ignarro Nitric oxide as a unique signaling molecule in the
Walker et al. Methods of reduction of cisplatin nephrotoxicity
Iadecola et al. Nitric oxide synthase inhibition and cerebrovascular regulation
CN1635882B (zh) 组合物在制备治疗听力丧失的药物中的用途
Maddrey et al. Effects of keto analogues of essential amino acids in portal-systemic encephalopathy
US5554638A (en) Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
RU98117618A (ru) Донорные окиси азота, способные снижать токсичность от лекарственных препаратов
Poylin et al. The NF‐κB inhibitor curcumin blocks sepsis‐induced muscle proteolysis
US20020049157A1 (en) Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
Grutzner et al. Effect of injury on pulpal levels of immunoreactive substance P and immunoreactive calcitonin gene-related peptide
JPH10194978A (ja) 一酸化窒素産生抑制剤
JPH02500368A (ja) 温血動物における腫瘍阻止方法
Hegyi et al. Commonly employed rodent models of experimental acute pancreatitis: their strengths and weaknesses, relevance to human disease, selection, and appropriate use
ES2314056T3 (es) Activadores de la anhidrasa carbonica para mejorar el aprendizaje y la memoria.
US20130096068A1 (en) Combination therapy with a proteasome inhibitor and a gallium complex
Caner et al. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa
Khanderia et al. Acute intermittent porphyria: pathophysiology and treatment
Murphy et al. Hemodynamic effects of the renin inhibitor CP-80,794 in several species
Malin et al. Nitric oxide synthesis inhibition attenuates behavioral actions of neuropeptide FF
PT1042286E (pt) Compostos imunomoduladores contendo grupos gama-glutamilo e beta-aspartilo e métodos para os preparar
CA2205056A1 (en) Method for reducing the severity of gastro-intestinal damage
Weinhold et al. Comparison of halogenated phenylalanine analogues as inhibitors as particle-bound and soluble tyrosine hydroxylase
Husband Psychoimmunology
AU634149B2 (en) Pain-killer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20120224